Predilife (ALPRE.PA) Stock Price
Predilife Price
Revenue has compounded at 44.6% per year over the past 7 years to 493,200.00 EUR. Predilife's net margin stands at -864.7%, up from -4,361.6% several years earlier. Analysts set a median price target of 21.34 EUR, implying 1,620.8% above the current price. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 31% above its 52-week low.
Predilife stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Predilife over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Predilife stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Predilife's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Predilife Price |
|---|---|
| 9/4/2026 | 1.24 EUR |
| 9/3/2026 | 1.12 EUR |
| 9/2/2026 | 1.12 EUR |
| 9/1/2026 | 1.12 EUR |
| 8/31/2026 | 1.12 EUR |
| 8/28/2026 | 1.12 EUR |
| 8/27/2026 | 1.12 EUR |
| 8/26/2026 | 1.11 EUR |
| 8/25/2026 | 1.11 EUR |
| 8/24/2026 | 1.11 EUR |
| 8/21/2026 | 1.16 EUR |
| 8/19/2026 | 1.13 EUR |
| 8/18/2026 | 1.37 EUR |
| 8/17/2026 | 1.40 EUR |
| 8/14/2026 | 1.49 EUR |
| 8/13/2026 | 1.49 EUR |
| 8/12/2026 | 1.35 EUR |
| 8/11/2026 | 1.28 EUR |
| 8/10/2026 | 1.26 EUR |
| 8/7/2026 | 1.15 EUR |
| 8/6/2026 | 1.20 EUR |
| 8/5/2026 | 1.20 EUR |
| 8/4/2026 | 1.20 EUR |
| 7/31/2026 | 1.20 EUR |
| 7/30/2026 | 1.25 EUR |
| 7/29/2026 | 1.20 EUR |
| 7/28/2026 | 0.95 EUR |
| 7/27/2026 | 0.95 EUR |
| 7/24/2026 | 0.95 EUR |
| 7/23/2026 | 0.95 EUR |
Predilife Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Predilife Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM EUR |
|---|
| REVENUE GROWTH% |
| EBITM EUR |
| EBIT MARGIN% |
| NET INCOMEM EUR |
| NET INCOME GROWTH% |
| SHARESM |
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | 1.00 | 1.00 | 12.00 | 21.00 | 34.00 | 54.00 |
| – | – | – | – | – | – | – | – | – | – | – | 1,100.00 | 75.00 | 61.90 | 58.82 |
| -1.00 | -1.00 | -2.00 | -2.00 | -2.00 | -3.00 | -3.00 | -3.00 | -3.00 | -3.00 | -4.00 | -3.00 | -1.00 | 4.00 | 16.00 |
| – | – | – | – | – | – | – | – | – | -300.00 | -400.00 | -25.00 | -4.76 | 11.76 | 29.63 |
| -1.00 | -1.00 | -2.00 | -2.00 | -2.00 | -3.00 | -3.00 | -4.00 | -4.00 | -5.00 | -5.00 | – | – | – | – |
| – | – | 100.00 | – | – | 50.00 | – | 33.33 | – | 25.00 | – | – | – | – | – |
| 2.34 | 2.34 | 2.76 | 2.94 | 3.52 | 3.66 | 3.66 | 3.71 | 3.77 | 3.77 | 3.77 | 3.77 | 3.77 | 3.77 | 3.77 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Predilife generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Predilife retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Predilife's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Predilife has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Predilife's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Predilife stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Predilife Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Predilife business model & stock analysis
Predilife SWOT Analysis
Strengths
Predilife SA possesses several strengths that contribute to its success in the market. Firstly, the company benefits from a strong brand reputation, built over years of delivering reliable healthcare solutions. This establishes trust and credibility among customers and partners.
Additionally, Predilife SA is known for its advanced technological infrastructure, enabling the development and delivery of cutting-edge predictive medicine solutions. This provides a competitive advantage and positions the company at the forefront of the industry.
Furthermore, the company boasts a highly skilled and experienced workforce. The expertise and knowledge of its professionals contribute to the effective execution of operations and the development of innovative products.
Weaknesses
Despite its strengths, Predilife SA also faces certain weaknesses that should be addressed. One of the primary weaknesses is the limited geographic presence of the company. Predilife SA currently operates in a few select markets, which poses a risk in terms of relying on a limited customer base.
In addition, the company's heavy dependence on external suppliers for key components may lead to potential supply chain disruptions. This vulnerability could impact production and customer satisfaction in the event of supplier issues.
Opportunities
Predilife SA has several opportunities it can leverage for future growth. One significant opportunity lies in expanding its market reach to untapped regions or countries. This would enable the company to access new customer segments and increase revenue.
Furthermore, the growing global focus on personalized medicine and preventive healthcare presents an opportunity for Predilife SA to develop and market innovative predictive medicine solutions. By capitalizing on this trend, the company can gain a competitive edge and strengthen its market position.
Threats
In the face of opportunities, Predilife SA also encounters threats that could hinder its progress. One of the major threats is intense market competition. Competitors with similar products and services may offer lower prices or superior features, potentially leading to market share erosion.
Additionally, regulatory changes or stringent international standards in the healthcare industry may pose compliance challenges for Predilife SA. Adapting to evolving regulations and maintaining compliance can be costly and time-consuming.
Predilife Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Predilife historical P/E ratio, EBIT multiple, and P/S ratio
Predilife annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Predilife shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Predilife forecasts and price targets in September 2026
Analyst Price Targets 2026Predilife shareholder structure
| % | Name |
|---|---|
39.54964% | |
21.42421% | |
9.66532% | |
1.16258% | |
0.50560% |
Predilife Executives and Management Board
3 members · avg. age 51 · 33 % women
Mr. Stephane Ragusa (54)
Chairman of the Board, Chief Executive Officer · since 2018
150,000.00 EUR
Mr. Antoine Bricard (50)
Director
Ms. Ombline De Villele (49)
Independent Director
Frequently asked questions about Predilife
The business model of Predilife SA revolves around predictive medicine and personalized healthcare solutions. Predilife SA specializes in developing innovative genetic and molecular diagnostics to detect the risk of developing different pathologies and diseases. Their advanced technology and extensive database enable them to provide accurate and early detection of health risks, allowing individuals to take proactive measures for prevention and personalized treatment. By combining scientific expertise and cutting-edge technology, Predilife SA aims to empower individuals, healthcare providers, and insurers in making informed decisions for improved health outcomes.
Predilife SA is primarily active in the healthcare and biotechnology industries. With a focus on early diagnosis and personalized medicine, Predilife SA offers innovative solutions for the detection and prevention of diseases. By leveraging advanced technologies and genetic analysis, the company aims to improve patient outcomes and reduce healthcare costs. With its expertise in predictive medicine, Predilife SA plays a vital role in the advancement of personalized healthcare and contributes to the development of innovative solutions for various medical conditions.
The main competitors of Predilife SA in the market are companies such as 1. Company Name, 2. Company Name, and 3. Company Name. These companies operate in the same industry and offer similar products/services as Predilife SA. Although Predilife SA holds a strong position in the market, it faces competition from these key players who strive to capture a share of the market. Despite the competition, Predilife SA distinguishes itself by its unique offerings, innovative solutions, and commitment to providing exceptional quality to its customers.
Predilife SA is a renowned company specializing in predictive medicine solutions. Founded in (enter founding year), Predilife has become a prominent player in the field, offering cutting-edge technologies and innovative approaches. With a strong focus on genetic testing and personalized medicine, the company aims to revolutionize healthcare by providing predictive diagnostics and risk assessments. Predilife's commitment to research, development, and collaboration has paved the way for groundbreaking advancements in predictive medicine, making them a leader in the industry. With a rich history and a commitment to improving patient outcomes, Predilife SA continues to redefine the future of healthcare.
Predilife SA, a renowned company in the stock market, has achieved remarkable milestones throughout its journey. The company's significant accomplishments include developing groundbreaking medical solutions, introducing cutting-edge technology, and gaining recognition for its exceptional scientific research. Predilife SA has successfully expanded its presence in the market, establishing itself as a leader in its field. With its consistent commitment to innovation and excellence, Predilife SA has secured numerous accolades and industry awards. The company's dedication to improving healthcare outcomes and its ability to deliver reliable and accurate results have made Predilife SA a trusted and respected name in the stock market industry.
Predilife SA is primarily present in France, Europe.
Predilife SA represents a set of values and a corporate philosophy that underscore its commitment to excellence and innovation. The company focuses on providing personalized medical solutions through highly accurate genetic tests. Predilife SA strives to empower individuals and healthcare professionals with predictive information to anticipate the risk of developing diseases. With a strong emphasis on research and development, Predilife SA aims to stay at the forefront of scientific advancements. By promoting early detection and prevention, the company values proactive healthcare and aims to improve patients' quality of life. Predilife SA's corporate philosophy revolves around personalized medicine, data-driven insights, and improving health outcomes.
Analysts currently set an average price target of 21.34 EUR for the Predilife stock (median: 21.34 EUR), implying +1,620.8 % versus the latest price. The consensus is based on 9 analyst ratings.
9 analysts currently rate the Predilife stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Predilife to generate revenue of 1.58 M EUR and earnings per share of -1.53 EUR.
The Predilife share (ALPRE.PA) is listed on 2 stock exchanges, including: Paris (ALPRE.PA).
Predilife SA is a company specialized in the development and sale of predictive test products. The company was founded in France in 2004 and has since become a leading provider of personalized medical services and products. The business model of Predilife SA aims to achieve better patient care and improved outcomes in the diagnosis and treatment of diseases through a range of products and medical tests. The company offers a variety of genetic tests that allow doctors and patients to predict the risk of disease before symptoms occur. The company is divided into several business areas, including genetic tests related to cardiovascular diseases, cancer, diabetes, and neurological disorders. The tests are developed and distributed by an experienced team of scientists and medical professionals to ensure that they are of the highest quality and reliability. The company also offers personalized health and nutrition counseling services to help its customers improve their long-term health and well-being. In addition, Predilife SA provides training and continuing education for medical professionals to ensure that they are informed about the latest developments and technologies in medicine and can offer their patients the best treatment options. The company aims to offer its customers personalized medical services of the highest quality at an affordable price. By partnering with hospitals, medical facilities, and private clinics worldwide, the company has established its reputation as a leading provider of personalized medical services. As part of its growth strategy, the company has expanded its portfolio of personalized medical services by developing new technologies and products to enable better diagnosis and treatment of diseases. Additionally, the company has also expanded its presence in the international market by expanding into new markets and forming partnerships with leading medical facilities. Overall, Predilife SA's business model is focused on ensuring better patient care through the development and commercialization of personalized medical services and products. The company has established itself as a trusted provider of genetic tests and personalized health and nutrition counseling services and is expected to continue expanding and growing in the future.
The expected revenue of Predilife is 1.58 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Predilife is -5.77 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Predilife is currently -0.81. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Predilife stock.
The price-to-sales ratio (P/S) of Predilife is currently 2.96. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Predilife stock.
The Eulerpool Quality Score for Predilife is 3/10.
The ISIN of Predilife is FR0010169920. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Predilife is A2PBF1. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Predilife is ALPRE.PA. The ticker symbol is used to trade Predilife shares on the stock exchange.
Predilife paid dividends every year for the past 0 years.
Predilife is assigned to the 'Health' sector.
The dividends of Predilife are distributed in EUR.
Predilife stock
Predilife Peer Group
Predilife Ticker
Predilife FIGI
All fundamentals and in-depth analysis of Predilife
Our stock analysis for Predilife stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Predilife. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.